Loading...

FITC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_FITC_102110
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
  • 53-6.7_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100705 50 µg $30
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100706 500 µg $99
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  2. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  3. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  4. Yao RQ, et al. 2022. Theranostics. 12:4606. PubMed
  5. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  6. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  7. Liu J, et al. 2019. Immunity. 50:600. PubMed
  8. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  9. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  10. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  11. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  12. Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed
  13. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  14. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  15. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  16. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  17. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  18. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  19. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  20. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  21. Paschall A, et al. 2015. J Immunol. 194: 2369-2379. PubMed
  22. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  23. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  24. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  25. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  26. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  27. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  28. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
  29. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  30. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  31. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  32. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  33. Apte S, et al. 2010. J Immunol. 185:998. PubMed
  34. Gotoh K et al. 2018. Cell reports. 25(7):1800-1815 . PubMed
  35. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  36. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  37. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  38. Wu K, et al. 2021. Aging (Albany NY). 13:. PubMed
  39. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  40. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  41. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  42. Morales D, et al. 2015. J Virol. 89:337. PubMed
  43. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  44. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  45. Okamoto T, et al. 2020. Cancer Res. 3580:80. PubMed
  46. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  47. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  48. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  49. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  50. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  51. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  52. Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed
  53. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  54. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  55. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  56. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  57. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  58. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  59. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  60. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  61. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  62. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  63. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  64. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  65. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  66. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  67. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  68. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  69. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  70. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  71. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  72. Wu J, et al. 2020. Immunity. 53:115. PubMed
  73. Köchl R, et al. 2020. Elife. 9:00. PubMed
  74. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  75. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  76. Xiao P, et al. 2019. J Exp Med. 216:337. PubMed
  77. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  78. Li Y, et al. 2019. Sci Rep. 9:6932. PubMed
  79. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  80. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  81. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  82. Drees J, et al. 2015. Anticancer Res. 35:843. PubMed
  83. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  84. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  85. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  86. Crowe JL, et al. 2020. Proc Natl Acad Sci U S A. 22953:117. PubMed
  87. Webster P, et al. 2018. Nat Commun. 9:2649. PubMed
  88. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  89. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  90. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  91. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  92. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  93. Yang J, et al. 2020. Nature. 586:572. PubMed
  94. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  95. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  96. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  97. Wan X, et al. 2018. Nature. 560:107. PubMed
  98. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  99. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  100. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  101. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  102. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  103. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  104. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  105. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  106. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  107. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  108. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  109. Nikolos F, et al. 2022. Nat Commun. 13:1487. PubMed
  110. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  111. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  112. Fang Y, et al. 2019. Aging (Albany NY). 11:4910. PubMed
  113. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  114. Du J, et al. 2018. AMB Express. 8:158. PubMed
  115. Holman P, et al. 2005. J Immunol. 174:3986. PubMed
  116. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  117. Jin C, et al. 2022. Oncoimmunology. 11:2099642. PubMed
  118. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  119. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  120. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  121. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  122. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  123. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  124. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  125. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  126. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  127. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  128. Zhan L, et al. 2022. Cancer Lett. 529:37. PubMed
  129. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  130. Wang L, et al. 2015. Cancer Immunol Res. 3: 1030-1041. PubMed
  131. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  132. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
  133. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  134. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  135. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  136. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  137. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  138. Riedl P, et al. 2009. J Immunol. 183:370. PubMed
  139. Feng D, et al. 2022. Nat Commun. 13:5554. PubMed
  140. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  141. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  142. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  143. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  144. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  145. Kvell K, et al. 2014. Immunobiology. 219:644. PubMed
  146. Dulken BW, et al. 2019. Nature. 571:205. PubMed
  147. Hu Z, et al. 2020. PLoS One. 15:e0228339. PubMed
  148. Ibrahim ML, et al. 2018. Cell Rep. 25:3036. PubMed
  149. Wu P, et al. 2020. Cancer Immunol Res. 8:1470. PubMed
  150. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  151. Shen L, et al. 2015. Cancer Immunol Res. 3:136. PubMed
  152. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  153. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  154. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  155. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  156. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  157. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  158. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  159. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  160. Panigrahy D, et al. 2019. J Clin Invest. 130:2964. PubMed
  161. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  162. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  163. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  164. Ren Y, et al. 2021. Nat Commun. 12:5405. PubMed
  165. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  166. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  167. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  168. Petriv N, et al. 2021. Oncoimmunology. 10:1874159. PubMed
  169. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  170. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  171. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  172. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
  173. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  174. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  175. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  176. Royzman D, et al. 2019. Front Immunol. 10:633. PubMed
  177. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  178. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  179. Li H, et al. 2022. iScience. 25:104481. PubMed
  180. Wang X, et al. 2022. Elife. 11:. PubMed
  181. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  182. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  183. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  184. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  185. Wen X, et al. 2021. World J Gastroenterol. 27:2834. PubMed
  186. Wang K, et al. 2021. Nat Commun. 12:4558. PubMed
  187. D'Cruz L, et al. 2014. J Immunol. 192:2227. PubMed
  188. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  189. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  190. Su M, et al. 2018. Immunol Cell Biol. 9:2448. PubMed
  191. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  192. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  193. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  194. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  195. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  196. Ying B, et al. 2022. Sci Transl Med. 14:eabm3302. PubMed
  197. Lee S, et al. 2021. Autophagy. 18:1062. PubMed
  198. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  199. Akhtar MN, et al. 2020. PLoS Pathog. 16:e1009136. PubMed
  200. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  201. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  202. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  203. Xie L, et al. 2020. Infect Immun. :88. PubMed
  204. Hayashi K, et al. 2020. Nat Commun. 4.832638889. PubMed
  205. Schlecker E, et al. 2012. J Immunol. 189:5602. PubMed
  206. Zhi Y, et al. 2020. Int J Mol Med. 45:1327. PubMed
  207. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
RRID
AB_312744 (BioLegend Cat. No. 100705)
AB_312745 (BioLegend Cat. No. 100706)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account